These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 36536192)
1. Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin. Sindelar M; McCabe D; Carroll E J Med Toxicol; 2023 Jan; 19(1):45-48. PubMed ID: 36536192 [TBL] [Abstract][Full Text] [Related]
2. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients. Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677 [TBL] [Abstract][Full Text] [Related]
3. Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion. Marsh J; Logan AT; Bilgili EP; Bowman LJ; Webb AR Am J Health Syst Pharm; 2024 Jun; 81(13):e345-e352. PubMed ID: 38347740 [TBL] [Abstract][Full Text] [Related]
4. Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant. Young C; Papiro T; Greenberg JH Pediatr Nephrol; 2023 Apr; 38(4):1387-1388. PubMed ID: 35982345 [TBL] [Abstract][Full Text] [Related]
5. Management and Outcome of COVID-19 Infection Using Nirmatrelvir/Ritonavir in Kidney Transplant Patients. Giguère P; Deschenes MJ; Van Loon M; Hoar S; Fairhead T; Pazhekattu R; Knoll G; Karpinski J; Parikh N; McDougall J; McGuinty M; Hiremath S Clin J Am Soc Nephrol; 2023 Jul; 18(7):913-919. PubMed ID: 37099447 [TBL] [Abstract][Full Text] [Related]
6. Tacrolimus toxicity due to enzyme inhibition from ritonavir. Snee I; Drobina J; Mazer-Amirshahi M Am J Emerg Med; 2023 Jul; 69():218.e5-218.e7. PubMed ID: 37173153 [TBL] [Abstract][Full Text] [Related]
7. Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug-drug interactions. Shen D; Gong Y; Qian Y; Zhu J; Gao J J Int Med Res; 2024 May; 52(5):3000605241247705. PubMed ID: 38698526 [TBL] [Abstract][Full Text] [Related]
8. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time". Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419 [TBL] [Abstract][Full Text] [Related]
9. Response to Comment on "Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin". Sindelar M; McCabe D; Carroll E J Med Toxicol; 2023 Jul; 19(3):309. PubMed ID: 36988815 [No Abstract] [Full Text] [Related]
10. Nirmatrelvir/ritonavir-induced elevation of blood tacrolimus levels in a patient in the maintenance phase post liver transplantation. Shiohira H; Arakaki S; Uehara W; Uehara H; Yamamoto K; Nakamura K J Infect Chemother; 2024 Jan; 30(1):77-80. PubMed ID: 37689137 [TBL] [Abstract][Full Text] [Related]
11. Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series. Dewey KW; Yen B; Lazo J; Seijo L; Jariwala R; Shah RJ; Quan D; Carpenter B; Paul Singer J; Breen K; Hays S; Florez R Transplantation; 2023 May; 107(5):1200-1205. PubMed ID: 36525555 [TBL] [Abstract][Full Text] [Related]
12. Nirmatrelvir Plus Ritonavir: First Approval. Lamb YN Drugs; 2022 Apr; 82(5):585-591. PubMed ID: 35305258 [TBL] [Abstract][Full Text] [Related]
13. Comment on "Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin". de Oliveira LM; da Silva Dal Pizzol T J Med Toxicol; 2023 Jul; 19(3):307-308. PubMed ID: 36988814 [No Abstract] [Full Text] [Related]
14. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19. Tomida T; Itohara K; Yamamoto K; Kimura T; Fujita K; Uda A; Kitahiro Y; Yokoyama N; Hyodo Y; Omura T; Yano I Drug Metab Pharmacokinet; 2023 Dec; 53():100529. PubMed ID: 37924724 [TBL] [Abstract][Full Text] [Related]
15. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT). Lemaitre F; Grégoire M; Monchaud C; Bouchet S; Saint-Salvi B; Polard E; ; ; ; ; ; Therapie; 2022; 77(5):509-521. PubMed ID: 35618549 [TBL] [Abstract][Full Text] [Related]
16. Case report: Paralytic ileus resulted from nirmatrelvir/ritonavir-tacrolimus drug-drug interaction in a systemic lupus erythematosus patient with COVID-19. Zhang W; Zhang X; Han J; Zhang W; Xu J; Zhang X; Bian H; Meng C; Shang D; Zhou Y; Wang D; Feng B Front Pharmacol; 2024; 15():1389187. PubMed ID: 38601471 [TBL] [Abstract][Full Text] [Related]
17. Supratherapeutic INR During Treatment With Nirmatrelvir/Ritonavir and Warfarin and Acute Illness With COVID-19: A Case Report. Dowd-Green C; Brown D; Wilson A; Streiff M J Pharm Pract; 2024 Dec; 37(6):1414-1418. PubMed ID: 38803049 [No Abstract] [Full Text] [Related]
18. Case report: Supratherapeutic tacrolimus concentrations with nirmatrelvir/ritonavir in a lung transplant patient: a case report using Rifampin for reversal. Xiong Y; Wang X; Li S; Zhang Q; Guo L; Chen W; Zhao Z; Liu L Front Pharmacol; 2023; 14():1285078. PubMed ID: 38026995 [TBL] [Abstract][Full Text] [Related]
19. Drug-drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS. Qin F; Wang H; Li M; Zhuo S; Liu W Expert Opin Drug Saf; 2023; 22(12):1321-1327. PubMed ID: 37477905 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]